Promoter profiles in plasma CfDNA exhibits a potential utility of predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients

Table 2 Clinical characteristics of 30 breast cancer patients undergoing EC-T chemotherapy

	All Patients	pCR	non-pCR	P-value
	(n = 30)	(n = 8)	(n = 22)	P-value
Age years, median (IQR)	50 (16)	47 (14)	51 (16)	0.635 ^*
Histological grade				1.000 ^*
< 3	22 (73.33%)	6 (75.00%)	16 (72.73%)
= 3	8 (26.67%)	2 (25.00%)	6 (27.27%)
HER2 status				1.000 ^#
Positive	10 (33.33%)	2 (25.00%)	8 (36.36%)
Negative	20 (66.67%)	6 (75.00%)	14 (63.64%)
ER status				0.235 ^*
Positive	21 (70.00%)	4 (50.00%)	17 (77.27%)
Negative	9 (30.00%)	4 (50.00%)	5 (22.73%)
PR status				0.673 ^*
Positive	22 (73.33%)	4 (50.00%)	8 (36.36%)
Negative	8 (26.67%)	4 (50.00%)	14 (63.64%)
Ki67 degree				0.122 ^*
≤ 30%	17 (56.67%)	5 (62.50%))	12 (54.55%)
> 30%	13 (43.33%)	3 (37.50%)	10 (45.45%)
Adjuvant mabs				0.232 ^#
Trastuzumab	6 (20.00%)	2 (25.00%)	4 (18.18%)
No	24 (80.00%)	6 (75.00%)	18 (81.82%)

Abbreviations: ^* Wilcoxon rank-sum test; ^# Pearson’s chi-squared test; IQR: interquartile range; ER, estrogen receptor; PR, progesterone; HER2, human epidermal growth factor receptor-2; EC-T: four cycles of epirubicin (E)/cyclophoshamide (C) followed by four cycles of docetaxel (T); pCR, pathological complete response; non-pCR, non-pathological complete response

ISSN: 1465-542X